ReviewRecent patents on nanotechnology2025
Recent Progression in Nanocarrier based Techniques to Address Fungal Infections and Patent Status in Drug Development Process.
Review in Recent patents on nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Zinc Oxide Nanoparticles in Modern Science and Technology: Multifunctional Roles in Healthcare, Environmental Remediation, and Industry.Nanomaterials (Basel, Switzerland) · 2025Review
- Synthesis of 2-Amino-4, 5-Diarylthiazole Derivatives and Evaluation of Their Anti-Molecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections are becoming one of the most common diseases in recent years, especially when it comes about dealing skin infections. Different drugs are available commercially with antifungal activity for topical application and are effective for treatment of mild to moderate fungal infections. However they lack dermal bioavailability due to their poor penetrability, and less retention at the site thereby resulting in poor efficacy. The remaining systemic treatment options available so far may cause adverse drug effects and many other complications. In recent years nano carrier based formulations promised to overcome the limitations of the conventional topical dosage forms. Lipid based nano carriers and their importance for potential use in delivery of antifungal agents for the treatment of superficial fungal infections have been well discussed in this review article. It comprises of different nano lipid systems involved in treatment of topical fungal infections, effect of different polymers on their size, stability, and their mechanistic action behind skin penetration and dermal retention of drug into deeper epidermal layers is also highlighted to depict recent efforts of researchers in this context. Further, addressing of the disease by novel drug delivery systems for the efficacious treatment, status of clinical trials, novel commercial formulations available for use in dermal drug delivery and patents claimed/granted in the respective fields have been discussed in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.